CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, has signed a contract for distribution of its Vergenix Flowable Gel product covering Belarus, Kazakhstan, Georgia, Azerbaijan, Armenia and Uzbekistan, it was reported on Monday.
The firm stated that it has received its first order for a fee running into hundreds of thousands of US dollars. According to the terms of the deal, CollPlant will deliver a part of the order immediately and the remainder over the next six months, with the contract covering a five-year period.
The product is based on the firm's rhCollagen technology aimed at treating acute and chronic hard-to-heal wounds including diabetic ulcers, pressure sores, surgical cuts and trauma wounds.
Maze Therapeutics reports positive Phase 2 data for MZE829 in patients with AMKD
Andel launches new direct-to-employer medication platform for GLP-1s
Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026
Cedar Health Research opens new embedded research site within Texas Native Health
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Alvotech reaches global settlement over aflibercept biosimilar patents
MedPal AI announces approval to supply Eli Lilly medicines in UK
Hanmi Pharmaceutical signs distribution agreement with Laboratorios Sanfer in Mexico
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735